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Background: Urinary bladder cancer is one of the most fatal and expensive diseases of industrialized world. Despite
the strenuous efforts, no seminal advances have been achieved for its clinical management. Given the importance of
metabolic reprogramming in cancer cell survival and growth, we have herein employed 3-BrPA, a halogenated
derivative of pyruvate and historically considered inhibitor of glycolysis, to eliminate bladder cancer cells with
highly oncogenic molecular signatures.
Methods: Bladder cancer cells were exposed to 3-BrPA in the absence or presence of several specific inhibitors.
Cell viability was determined by MTT and flow-cytometry assays; cell death, signaling activity and metabolic integrity by
Western blotting and immunofluorescence; mutant-gene profiling by DNA sequencing; and gene expression by
RT-sqPCR.
Results: 3-BrPA could activate dose-dependent apoptosis (type 1 PCD) and regulated necrosis (type 3 PCD) of T24
(grade III; H-RasG12V; p53ΔY126), but not RT4 (grade I), cells, with PARP, MLKL, Drp1 and Nec-7-targeted components
critically orchestrating necrotic death. However, similarly to RIPK1 and CypD, p53 presented with non-essential
contribution to 3-BrPA-induced cellular collapse, while reactivation of mutant p53 with PRIMA-1 resulted in strong
synergism of the two agents. Given the reduced expression of MPC components (likely imposing mitochondrial
dysfunction) in T24 cells, the suppression of constitutive autophagy (required by cells carrying oncogenic Ras; also, type
2 PCD) and derangement of glucose-homeostasis determinants by 3-BrPA critically contribute to drug-directed
depletion of ATP cellular stores. This bioenergetic crisis is translated to severe dysregulation of Akt/FoxO/GSK-3,
mTOR/S6, AMPK and MAPK (p44/42, p38 and SAPK/JNK) signaling pathways in 3-BrPA-treated T24 cells. Sensitivity
to 3-BrPA (and tolerance to glucose deprivation) does not rely on B-RafV600E or K-RasG13D mutant oncogenic proteins,
but partly depends on aberrant signaling activities of Akt, MAPK and AMPK kinases. Interestingly, MCT1- and
macropinocytosis-mediated influx of 3-BrPA in T24 represents the principal mechanism that regulates cellular
responsiveness to the drug. Besides its capacity to affect transcription in gene-dependent manner, 3-BrPA can
also induce GLUT4-specific splicing silencing in both sensitive and resistant cells, thus dictating alternative routes
of drug trafficking.
Conclusions: Altogether, it seems that 3-BrPA represents a promising agent for bladder cancer targeted therapy.
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Urothelium lines the inner surfaces of almost the entire
urinary track, including bladder. Urothelial carcinoma of
the bladder is a major cause of mortality worldwide and
it ranks fifth among all cancers in the Western world,
with an estimated 150,000 deaths per year [1, 2]. Bladder
cancer is classified as either a low-grade, non-muscle-
invasive disease, or a high-grade, muscle-invasive disease,
which is likely to metastasize [1, 3]. The main genetic al-
terations underlying low-grade papillary tumor develop-
ment involve FGFR3, H-Ras and mTOR pathway member
genes, whereas progression to high-grade invasive urothe-
lial carcinoma depends on p53 and Rb tumor-suppressor
networks [1, 3]. However, an integrated study of 131 inva-
sive bladder carcinomas revealed dysregulation of PI3K/
Akt/mTOR and RTK/Ras/MAPK pathways in 42 % and
44 % of the tumors, respectively [2]. Interestingly, distinct
basal (“mesenchymal”-like) and luminal (“epithelial”-like)
subtypes of muscle-invasive bladder cancer, with different
sensitivities to frontline chemotherapy, have been recently
identified [4, 5]. Treatment of the disease has not ad-
vanced, in the past 30 years, beyond surgery and cisplatin-
based combination chemotherapy, which is only effective
in ~40 % of cases [2, 4, 6]. Therefore, novel strategies that
target specific pathways in the malignant cell must suc-
cessfully evolve and promptly pass the proof-of-principle
tests in preclinical models and clinical trials [1, 3, 6].
Reprogramming of energy metabolism has recently
emerged as a new hallmark of cancer [7]. The best charac-
terized metabolic phenotype of tumor cells is the Warburg
effect, which is a shift from ATP generation through mito-
chondrial oxidative phosphorylation to ATP generation
through glycolysis, even under normal oxygen concentra-
tions [8, 9]. Aerobic glycolysis seems to play an important
role in supporting the large-scale biosynthetic programs
that are required for active cell proliferation. Glycolytic
fueling has been associated with the PI3K/Akt/mTOR and
AMPK signaling pathways, the Ras activated oncogene
and the mutant p53 tumor suppressor protein, critically
contributing to uncontrolled growth and attenuation of
apoptosis in cancer cells [7–9]. Hence, the targeting of
metabolic transformation opens a new therapeutic win-
dow in human malignancy [10, 11].
3-BrPA is a halogenated pyruvate derivative and a strong
alkylating agent towards cysteine residues in proteins [12].
It directly targets the GAPDH glycolytic regulator, inhibit-
ing its enzymatic activity and causing depletion of cellular
ATP pool [12–14]. Moreover, 3-BrPA covalently modifies
HK2 protein, a critical determinant in the first step of
glycolysis, promoting its dissociation from mitochondria,
opening PTPC and inducing cell death [12, 15, 16]. How-
ever, the detailed mechanisms responsible for the ability
of 3-BrPA to eradicate cancer cells remain to be fully
elucidated [12].Here, we provide evidence for the therapeutic exploit-
ation of Warburg effect in solid tumors, by dissecting the
cytotoxic pathways of 3-BrPA in human urinary bladder
cancer cells. Drug proved to activate p53-independent
apoptotic and necrotic -but not autophagic- programs,
and to induce strong irregularities in Akt/mTOR, MAPK
and AMPK signaling functions. New targets and action
modes of 3-BrPA have been identified for the first time in
a bladder cancer environment.
Results
3-BrPA induces dose-dependent apoptotic and non-
apoptotic death in bladder cancer cells
By employing MTT-based protocols, we herein reveal the
cell type-specific cytotoxicity of 3-BrPA in bladder carcin-
oma. In contrast to RT4 (grade I; wild-type p53) that
remained unaffected, T24 (grade III; mutant p53) bladder
cancer cells presented with strong reduction of survival
proficiency in response to 3-BrPA (Fig. 1a, b and d).
Drug’s cytotoxicity could be detected even after 5 min of its
administration (Fig. 1c), while low cell confluency proved
to enhance the detrimental effects (Fig. 1d). Flow cytome-
try analysis of control and 3-BrPA-treated cells, after their
staining with AnnexinV-FITC and 7AAD, evidenced the
ability of the drug to orchestrate cell death specifically in
T24 but not RT4 cells (Fig. 1e). Interestingly, the new
T24-X cell line established herein by T24-derived tumor
xenografts in SCID mice (Additional file 1: Figure S1)
proved more tolerant to 3-BrPA compared to T24 cells
(Fig. 1b and f), indicating the in vivo acquisition of add-
itional mutations. Light microscopy imaging (Additional
file 1: Figure S1) and cytogenetic analysis (data not shown)
validated the clonal origin of T24-X from T24 cells.
Processing of whole-cell protein extracts through Western
blotting, demonstrated the ability of 3-BrPA to induce acti-
vation of caspase repertoire (Fig. 1g) and typical cleavage of
its cognate substrates (Fig. 1h), hallmarks of extrinsic and
intrinsic apoptotic pathways [17, 18], exclusively in T24 and
T24-X cells exposed to 75 (low dose) but not 100 and 125
μΜ (high doses) of the drug. Surprisingly, distinct patterns
of ICAD (high MW forms) post-translational modifications,
and Lamin A/C (~55 kDa fragment) and PARP (~53 kDa
fragment) proteolytic profiles were obtained at 3-BrPA
high doses (Fig. 1h). Conclusively, 3-BrPA proved able
to quickly kill bladder cancer cells in a cell type-specific
and cell density-based manner, through induction of dose-
dependent apoptotic and non-apoptotic death.
Exposure of bladder cancer cells to 3-BrPA results in
activation of regulated necrosis and suppression of
autophagy
The aberrant processing of PARP observed at high drug
doses (Fig. 1h) could be tightly associated with functional
irregularities of the protein. Given that PARP over-
Fig. 1 (See legend on next page.)
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Fig. 1 Bladder cancer cells undergo cell type-specific and dose-dependent apoptotic and non-apoptotic death in response to 3-BrPA. (a, b and f)
MTT cytotoxicity assays of RT4 (a), T24 (b) and T24-X (f) cells, grown at ~60 % confluency and treated with the indicated doses (μM) of 3-BrPA
(stock in ddH2O) for 24 h (also, see Additional file 1: Figure S1 and Additional file 10: Table S2). (c) MTT cytotoxicity assays of T24 cells, grown at ~60 %
confluency and treated with 125 μM of 3-BrPA for the indicated time periods (min). (d) MTT cytotoxicity assays of T24 and RT4 cells, seeded at
the indicated confluency (low: ~30 %; medium: ~60 %; high: ~90 %) and exposed to 100 (T24) or 300 μM (RT4) of 3-BrPA, for 24 and 72 h, respectively.
(a-d and f) Results are reported as mean ± standard deviation of triplicates of, at least, three independent experiments. *P < 0.001. (e) Representative
flow cytometry charts (AnnexinV-FITC and 7AAD staining) of RT4 and T24 cells, grown at ~60 % confluency and treated with the indicated doses of
3-BrPA for 24 h. (g-h) Representative Western blotting profiles of whole-cell protein extracts obtained from RT4, T24 and T24-X cells, seeded at ~60 %
confluency and exposed to the indicated doses of 3-BrPA for 24 h. The proteins examined were Caspase-8, Caspase-9, Caspase-3 (g), PARP, Lamin A/C
and ICAD (h), while Actin was used as molecule of reference. Bracket and asterisk denote the high MW forms of ICAD protein (h). Flow cytometry (e)
and Western blotting (g-h) experiments were repeated three independent times each
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[18, 19], PJ-34, a PARP-specific inhibitor [18, 20], was
herein employed in an effort to revert the 3-BrPA cytotoxic
phenotype. Indeed, treatment of T24 and T24-X with PJ-34
provided cells with a significant survival advantage -as
shown by MTT assays- against 100 and 125 μΜ of 3-BrPA
(Fig. 2a-b), therefore indicating the drug-induced over-
activation of PARP and its capacity to promote cell
necrosis in a bladder cancer setting.
Inhibition of Caspase-8 turns on the necrotic function of
RIPK1/RIPK3/MLKL signaling axis [21–23], which succes-
sively triggers the Drp1-mediated mitochondrial fragmenta-
tion, a likely obligatory step for necrosis execution [24].
Thereby, the observed absence of active Caspase-8 at high
drug doses (Fig. 1g) prompted us to pharmacologically
eliminate the RIPK1/MLKL/Drp1 necrotic activity. In con-
trast to Nec-1 and Nec-5, two specific inhibitors of RIPK1
[19, 21–25], which could not offer resistance to the drug
(Fig. 2c-d), Nec-7, a necrostatin family member with
unknown target(s) [26], proved able to remarkably rescue
T24 cells from 100 and 125 μM of 3-BrPA. Intriguingly, a
Nec-7-mediated vacuolization of the cytoplasm was
observed (Fig. 2e). Furthermore, both NSA and Mdivi-1,
previously reported to specifically block the MLKL and
Drp1 respective functions [22–24, 27], significantly
increased the survival capacity of T24 cells in response to 3-
BrPA high doses (Fig. 2f-g). Besides PARP and MLKL/Drp1,
necrosis can be also regulated by the distinct p53/CypD axis
that targets to open the mitochondrial PTPC [28, 29]. How-
ever, by employing CsA, in order to eliminate CypD activity
[28], T24 cells could not be rescued from 3-BrPA (Fig. 2h).
Overall, it seems that PARP, MLKL/Drp1 and novel Nec-7-
targeted, but not RIPK1 and CypD/PTPC, necrotic axes
critically modulate 3-BrPA cytotoxicity in T24 cells.
Depending on the cellular setting, (macro)autophagy can
act potently to either promote or inhibit tumorigenesis
[30, 31]. Surprisingly, as shown by Western blotting, in con-
trast to RT4, T24 and T24-X cells presented with high levels
of basal autophagy, which were severely downregulated in
response to 3-BrPA (Fig. 2i). Interestingly, Doxorubicin, used
as control drug, proved able to induce autophagy in RT4
but not T24 cells (Additional file 2: Figure S2A). It has beenpreviously reported that T24 cells require strong constitutive
autophagy for normal growth and survival [32]. Therefore,
besides regulated necrosis (Fig. 2a-h), suppression of
autophagy (Fig. 2i) must be critically implicated in 3-BrPA-
mediated bladder cancer cell death.
Presumable depletion of cytosolic NAD+ by over-
activated PARP, mitochondrial fragmentation by dere-
pressed MLKL/Drp1 and exhaustion of key metabolic inter-
mediates by disrupted autophagy dictate the development
of a strong bioenergetic crisis. Indeed, treatment of T24
cells with 3-BrPA resulted in a dramatic and quick deple-
tion of cellular ATP levels (Fig. 2j and Additional file 2:
Figure S2B). Furthermore, the notably reduced concentration
of cellular lactate in response to the drug (Fig. 2k) unveiled
the glycolytic character of T24 and indicated the power of
3-BrPA to impair glycolysis, another essential process for
ATP generation, in bladder cancer cells (see Fig. 7).
3-BrPA causes genomic toxicity in bladder cancer cells,
but does not mobilize p53 function: synergism of 3-BrPA
and PRIMA-1
Since γH2A.X represents a bona fide marker of DNA
double-strand break formation [33], control and drug-
treated RT4, T24 and T24-X cells were processed through
Western blotting using a suitable p-H2A.X-Ser139 primary
antibody. In contrast to RT4 that remained unaffected, T24
and T24-X cells proved significantly vulnerable to geno-
toxic activity of 3-BrPA (Fig. 3a), while upon exposure to
Doxorubicin reference drug all three cell types presented
with even stronger genotoxic responses (Fig. 3b). Interest-
ingly, a prominent resistance of T24-X, compared to T24,
cells was observed for 3-BrPA, but not Doxorubicin.
Despite the accumulation of genetic defects, T24 and
T24-X cells could not mobilize and activate, through
stabilization and targeted phosphorylation, the p53 tumor
suppressor protein, a guardian of genome integrity and
critical mediator of apoptosis, autophagy, necrosis and me-
tabolism [28, 34, 35], after administration of 3-BrPA (Fig. 3a
and Additional file 3: Figure S3A). Likewise, 3-BrPA failed
to enhance transcription of BAX, PUMA, NOXA, TIGAR
and SESTRIN-1 genes, bona fide targets of wild-type
p53 [34, 35], in T24 cells (Additional file 6: Figure S6).
Fig. 2 (See legend on next page.)
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Fig. 2 3-BrPA activates regulated necrosis and impairs autophagy in bladder cancer cells. (a-b) MTT cytotoxicity assays of T24 (a) and T24-X (b) cells, grown
at low confluency (to maximize cells’ sensitization to 3-BrPA; Fig. 1d) and exposed to the indicated doses of 3-BrPA for 24 h, in the absence or presence
(pre-incubation for 2 h) of 10 μM PJ-34 (stock in ddH2O). (c-h) MTT cytotoxicity assays of T24 cells, seeded at low confluency and treated with the indicated
doses of 3-BrPA for 24 h, in the absence or presence (pre-incubation for the denoted time) of 10 or 100 μM Nec-1 (c), 50 or 100 μM Nec-5 (d), 150 or
300 μM Nec-7 (e), 5 or 10 μM NSA (f), 75 or 100 μM Mdivi-1 (g) and 1 or 10 μM CsA (h). Each inhibitor remained in the growth medium with half of its
initial respective concentration for 24 h more, post-pre-incubation. Stock solutions of all inhibitors (c-h) were prepared in DMSO. (c) Two different providers
of Nec-1 were independently examined; Sigma-Aldrich (Missouri, USA) and Santa Cruz Biotechnology Inc. (Texas, USA). MTT viability rates obtained from
the cocktail of 3-BrPA with each death inhibitor (PJ-34, Nec-1, Nec-5, Nec-7, NSA, Mdivi-1 and CsA) were compared to the respective ones of 3-BrPA alone
and, after their normalization with values derived from inhibitor only, versus its cognate solvent, they were presented in fold (x) of inhibitor-induced cell
survival increase. (a-h) Data are reported as mean ± standard deviation of triplicates of three independent experiments. *P < 0.001. (e) Light
micrographs: T24 cells respectively treated with 150 μM of Nec-7, 100 μM of 3-BrPA, or both, for 24 h. Scale bars: 4 μm. (i) Representative
(three independent experiments) Western blotting profiles of whole-cell protein extracts derived from RT4, T24 and T24-X cells, grown at
~60 % confluency and exposed to the indicated doses of 3-BrPA for 24 h. The proteins examined were Atg5, Atg7, Atg12, Beclin-1 and LC3B, while
Actin was used as molecule of reference (also, see Additional file 2: Figure S2). (j-k) Quantitative assessment of ADP and ATP cellular contents
(ADP/ATP ratio) (j), and lactate cellular levels (k) of T24 cells, seeded at ~60 % confluency and treated with the indicated doses of 3-BrPA for 2
(j) and 4 h (k), respectively (also, see Additional file 2: Figure S2). x: fold of ADP/ATP ratio rise (j) and lactate concentration reduction (k). (j-k)
Results are denoted as mean ± standard deviation of triplicates of three independent experiments. *P < 0.001
Konstantakou et al. Molecular Cancer  (2015) 14:135 Page 6 of 26Nevertheless, Doxorubicin could upregulate p53 protein
and activity levels in all three cell types, albeit strongly in
RT4 (p53wt), and weakly in T24 and T24-X (p53mt) cells
(Fig. 3b and Additional file 3: Figure S3B). To ensure that
the unresponsiveness of wild-type p53 to 3-BrPA is not
associated with impaired influx of the drug in RT4 cells (see
Fig. 8), but rather represents an intrinsic feature of the
protein and its microenvironment, we reasoned to examine
wild-type p53 in certain settings, such as T24 cells, that
clearly facilitate the cellular uptake of 3-BrPA (see Figs. 1
and 8). Therefore, and given the differential status of p53
gene between RT4 (wild-type) and T24 (mutant), we
attempted to over-express, through transient transfection,
the wild-type human p53 protein in T24 cells, aspiring not
only to, reliably, evaluate protein’s response to the drug, but
to also rescue T24 from 3-BrPA-mediated cytotoxicity. If the
wild-type p53 (basal activity) is the critical factor that renders
RT4 cells resistant to 3-BrPA, its (p53wt) over-expression in
T24 (p53mt) could provide cells with a -significant- survival
advantage against the drug. Despite the capacity of trans-
fected p53 to be strongly activated in response to Doxorubi-
cin, therefore indicating its functional competence (Fig. 3c),
it (p53) proved unable to revert (even partly) the 3-BrPA-
induced toxic phenotype in T24 cells (Fig. 3d). Interestingly,
the transfected wild-type p53 protein was notably downregu-
lated in 3-BrPA-treated cells (Fig. 3c), underscoring the
different modes of action of the two drugs. Altogether, it
seems that 3-BrPA exerts its genotoxic power in bladder
cancer cells through a p53-independent mechanism.
Given the ability of PRIMA-1 to reactivate mutant p53
[36], RT4, T24 and T24-X cells were exposed to PRIMA-1,
in the presence or absence of 3-BrPA, examining the
proficiency of endogenous mutant p53 (ΔY126), upon its
functional restoration, to sensitize bladder cancer cells to 3-
BrPA. It proved that PRIMA-1 could upregulate the p53-
target gene Mdm2 (data not shown), without affecting total
or phosphorylated p53 protein contents (data not shown),in T24 cells, thus indicating its (PRIMA-1) specific mode of
action. But most importantly, PRIMA-1 could selectively
eradicate T24 and T24-X, but not RT4, cells in a dose-
specific manner (Fig. 3e). It must be the ability of PRIMA-1
to reactivate the mutant p53 form (ΔY126) in T24, by cova-
lent binding to thiol groups of critical cysteine residues in
protein’s core domain, as previously reported for different
mutant p53 forms [36], ultimately driving cells to death.
Notably, PRIMA-1 could strongly synergize with 3-BrPA,
promoting cell death exclusively in the vulnerable T24 and
T24-X (p53mt) cells (Fig. 3f). Interestingly, T24-X presented
with higher sensitivity, compared to T24 cells, either to
PRIMA-1 alone (Fig. 3e) or to PRIMA-1/3-BrPA combin-
ation (Fig. 3f). Thereupon, this drug cocktail holds promise
for helping to fight urothelial bladder malignancies with
highly oncogenic molecular signatures.
Bladder cancer cells are subjected to severe signaling
dysregulation in response to 3-BrPA
Since the Akt/FoxO/GSK-3 signaling axis is critically impli-
cated in cell metabolism and death [37–40], mTOR/S6 in
translation, metabolism, ATP production and autophagy
[40–42], AMPK in metabolism, energy homeostasis and
autophagy [37, 43, 44], and the MAPK family members
p44/42, p38 and SAPK/JNK in cell proliferation, metabolism
and death [37, 45–47], we employed a Western blotting
protocol examining the potency of 3-BrPA to harm each
pathway’s signaling integrity in a bladder cancer context.
Necrotic doses of 3-BrPA proved capable to drastically re-
duce the basal signaling activities (reflected on phosphoryl-
ation profiles) of Akt/FoxO/GSK-3 (Fig. 4a-b), mTOR/S6
(Fig. 4c), AMPKα (Fig. 4c), and p44/42 MAPK, p38 MAPK
and SAPK/JNK (Fig. 4d) respective pathways, in T24 and
T24-X cells. However, the p-Akt-Thr308 (Fig. 4a) and p-p44/
42 MAPK-Thr202/Tyr204 (Fig. 4d) kinase forms could be
notably upregulated at 75 μM of the drug, thus indicating
the distinct signaling requirements of apoptotic and necrotic
Fig. 3 (See legend on next page.)
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Fig. 3 p53 is not engaged in genotoxic responses of bladder cancer cells to 3-BrPA: 3-BrPA and PRIMA-1 cooperative actions. (a-b) Representative (three
independent experiments) Western blotting profiles of whole-cell protein extracts derived from RT4, T24 and T24-X cells, grown at ~60 % confluency and
exposed to the indicated doses of 3-BrPA (a) or Doxorubicin (b) for 24 h. The proteins examined were p-H2A.X-Ser139, H2A.X, p-p53-Ser15, p-p53-Ser392 and
p53, while Actin was used as molecule of reference (also, see Additional file 3: Figure S3). p: phosphorylation. (c) Representative (three independent
experiments) Western blotting profiles of whole-cell protein extracts obtained from untransfected (−) and transiently transfected (CMV-p53 or CMV control
vector) T24 cells, treated (48 h post-transfection) with the indicated doses of 3-BrPA (left panel) or Doxorubicin (right panel) for 24 h. The proteins examined
were p-p53-Ser15 and p53, while Actin was used as molecule of reference. (d) MTT cytotoxicity assays of T24 cells, after their transient transfection with
either CMV-p53 expression vector (gray bars) or CMV control (empty) vector (white bars) and subsequent exposure (48 h post-transfection) to the indicated
doses of 3-BrPA for 24 h. (d) Data are reported as mean ± standard deviation of triplicates of three independent experiments. *P< 0.001. (e) MTT
cytotoxicity assays of RT4, T24 and T24-X cells, grown at ~60 % confluency and treated with the indicated doses of PRIMA-1 (stock in ddH2O) for 6 h and
half of its initial respective concentrations for 24 h more. (f) MTT cytotoxicity assays of RT4, T24 and T24-X cells, seeded at ~60 % confluency and
exposed to the indicated doses of 3-BrPA in the presence of PRIMA-1 (pre-incubation for 6 h, with 100 or 200 μM) for 24 h (5, 6, 8 and 9). PRIMA-1
remained in the growth medium, containing (5, 6, 8 and 9) or not (4 and 7) 3-BrPA, with half of its initial respective concentrations for 24 h more,
post-pre-incubation (also, see Fig. 3e). 3-BrPA (50 or 75 μM) alone was added to the cells for 24 h (2 and 3; also, see Fig. 1). PI: pre-incubation.
(e-f) Results are denoted as mean ± standard deviation of triplicates of three independent experiments. *P < 0.001
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form, most likely derived from an alternative splicing
process [45, 48], was strongly induced at 100 and 125 μM of
3-BrPA in the susceptible cells (Fig. 4d). It must be its modi-
fied molecular conformation that disables the ~47 kDa form
to be specifically recognized by the polyclonal antibody of
total p44/42 MAPK kinase. However, the new antigenic epi-
tope, being shaped in response to 3-BrPA, does not seem to
hinder, but rather significantly favor, the high-affinity binding
of p-p44/42 MAPK-Thr202/Tyr204 antibody to 47 kDa novel
form. This 47 kDa phosphorylated protein, together with
the drug-produced p-SAPK/JNK-Thr183/Tyr185 novel form
of ~39 kDa (Fig. 4d), presumably being generated via non-
canonical splicing, could be tightly associated with regulated
necrosis operating in 3-BrPA-treated T24 cells. The signal-
ing capacity of 47 kDa protein may resemble the abnormal
one featured by ERK1b (p44/42 MAPKb), a 46 kDa differen-
tially spliced isoform that enhances Elk1 (cognate target)
activity, resists phosphatase-mediated de-phosphorylation
and responds to osmotic shock more efficiently than p44/42
MAPK [48, 49]. The significantly reduced expression of 47
and 39 kDa phosphorylated protein forms in T24-X cells
(Fig. 4d) might justify their (T24-X) higher resistance,
compared to T24, to 3-BrPA cytotoxic power (Fig. 1).
In contrast to Akt and p44/42 MAPK total protein levels
that remained unaffected (Fig. 4a and d), the rest of signaling
mediators presented with different degrees of dose-
dependent downregulation in their total cellular contents
after drug administration (Fig. 4b-d). Remarkably, it is these
two kinases (Fig. 4a and d), together with GSK-3β (Fig. 4b)
and AMPKα (Fig. 4c) ones, that proved to undergo “ladder-
like” post-translational modifications. However, none of the
Akt, GSK-3β, AMPKα and p44/42 MAPK respective phos-
phorylation profiles figured with high MW forms (data not
shown), strongly reflecting settings of cellular bioenergetic
crisis (Fig. 2j) and likely indicating the harmful effects of
post-translational modifications (e.g. pyruvylation) in kinase
signaling functions in 3-BrPA-treated T24 and T24-X cells
during regulated necrosis. A similar damaging mechanism,besides ATP depletion, could also operate in the case of
~300 kDa mTOR kinase novel form, strongly produced in
T24-X cells at drug necrotic doses (Fig. 4c). Overall, we
herein reveal that 3-BrPA causes detrimental dysregulation
of multiple signaling pathways, compelling bladder cancer
cells to regulated necrotic death.
Akt and p44/42 MAPK basal signaling activities, but not
B-RafV600E and K-RasG13D oncogenic functions, are critically
implicated in the sensitivity of T24 cells to 3-BrPA
The constitutively upregulated activities of Akt and p44/42
MAPK kinases in T24, but not RT4, cells (Fig. 4), likely em-
anated from the T24-specific mutant H-RasG12V oncogenic
protein [32], dictate their crucial roles in the differential
resistance of examined cells to 3-BrPA. Pre-incubation of
T24 cells with either LY294002, a potent PI3K/Akt inhibi-
tor [50], or U0126, a strong MAPKK(1/2)/MAPK(p44/42)
inhibitor [45], resulted in the elimination of cognate kinase
activities (Fig. 5a-b) and inhibitor-dependent increase of cell
survival at 3-BrPA necrotic doses (Fig. 5c-d). Both inhibi-
tors were employed at doses that produced the strongest
functional suppression of their respective kinase targets.
Despite the rather moderate cytotoxicity observed upon cell
exposure to LY294002 and the weak one after treatment
with U0126, each inhibitor could effectively counteract,
albeit by its own specific manner, the deleterious power of
3-BrPA, providing T24 with strong survival capacity
(Fig. 5a-d). Similarly, AICAR, a genuine AMPK agonist
[43], proved capable to significantly rescue T24 cells from
drug-mediated necrotic death (Fig. 5e). It seems that
aberrant signaling repertoires differentially control 3-BrPA-
induced cytotoxicity in T24 cells.
The sensitivity of TCCSUP (PIK3CAE545K; grade IV), but
not RT112 (grade I-II), cells to 3-BrPA (Fig. 5f-g) corrobo-
rates drug’s proficiency to specifically target bladder cancer
cells carrying oncogenic H-Ras and/or aberrant PI3K/Akt
signaling. Sequence analysis of genomic DNA demonstrated
that RT4, T24, T24-X, RT112 and TCCSUP do not
contain the B-RafV600E and K-RasG13Dmutant alleles (Fig. 6a,
Fig. 4 (See legend on next page.)
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Fig. 4 3-BrPA induces severe dysregulation of multiple signaling pathways in bladder cancer cells. (a-d) Representative (three independent experiments)
Western blotting profiles of whole-cell protein extracts obtained from RT4, T24 and T24-X cells, grown at ~60 % confluency and exposed to the indicated
doses of 3-BrPA for 24 h. The proteins examined were p-Akt-Thr308, p-Akt-Ser473, Akt (a), p-FoxO1-Thr24/p-FoxO3a-Thr32, FoxO1, p-GSK-3α/β-Ser21/9,
p-GSK-3β-Ser9, GSK-3α, GSK-3β (b), p-mTOR-Ser2448, mTOR, p-S6-Ser235/236, S6, p-AMPKα1-Ser485/p-AMPKα2-Ser491, p-AMPKα-Thr172, AMPKα (c),
p-p44/42 MAPK-Thr202/Tyr204, p44/42 MAPK, p-p38 MAPK-Thr180/Tyr182, p38 MAPK, p-SAPK/JNK-Thr183/Tyr185 and SAPK/JNK (d), while Actin was
used as molecule of reference. Brackets and asterisks denote the high MW forms of Akt (a), GSK-3β (b), AMPKα (c) and p44/42 MAPK (d) kinases
Konstantakou et al. Molecular Cancer  (2015) 14:135 Page 10 of 26Additional file 4: Figure S4 and Additional file 10: Table S2),
thus uncoupling bladder cancer cell susceptibility to 3-BrPA
from B-RafV600E and/or K-RasG13D oncogenic functions,
contrary to findings of a previous report in colorectal carcin-
oma [51]. However, similarly to colorectal cancer cells [51],
bladder cancer cells that were sensitive to 3-BrPA (T24,
T24-X and TCCSUP) presented with strong survival capaci-
ties in glucose-deprived environments (Fig. 6c, d and f), and
vice versa (Fig. 6b and e) (Additional file 10: Table S2). It
is likely that the H-RasG12V-related, robust constitutive
autophagy in T24 [32] and T24-X (Fig. 2i) can successfully
compensate for lack of glucose, supplying cells with the
necessary metabolic substrates for survival.
3-BrPA harms key determinants of glucose uptake and
metabolism in bladder cancer cells
HK2 is required for glucose starvation-induced autophagy
[42] and oncogenic K-Ras-directed robust tumorigenesis
[52], while it can be phosphorylated by Akt [38] and
targeted by 3-BrPA [12, 15, 16]. In parallel, GAPDH is func-
tionally inhibited by 3-BrPA [12–14], while it can bind to
activated Akt, leading to its stabilization [53]. Hence, we
examined the structural integrity of both glycolytic enzymes
in drug-treated bladder cancer cells. Exposure of T24 and
T24-X to 3-BrPA necrotic doses resulted in severe down-
regulation of GAPDH, but not HK2, expression levels
(Fig. 7a), thus indicating glycolytic failure, bioenergetic crisis
(Fig. 2j-k and Additional file 2: Figure S2B) and activated
Akt elimination (Fig. 4a). However, the prominent HK2
form of ~145 kDa (Fig. 7a), likely derived from drug-
induced pyruvylation [13, 15], might downgrade T24
glycolytic competence, rendering cells more vulnerable to
3-BrPA compared to T24-X ones.
Furthermore, 3-BrPA necrotic doses proved capable to
dramatically reduce the constitutive expression levels of
GLUT4 (featured with smaller MW) (Fig. 7b), the principal
transporter of glucose uptake [54, 55], and AS160 (Akt
substrate), Rab10 and Tug proteins (together with Rab2A,
Rab8A and Rab14 genes), critical determinants of GLUT4
trafficking [54, 55], in T24 and T24-X (Fig. 7a and
Additional file 5: Figure S5A), indicating drug’s proficiency
to potently perturb glucose uptake in bladder cancer cells.
Interestingly, despite the 3-BrPA-induced downregulation
of GLUT1 (and GLUT3) gene activity in sensitive cells
(Fig. 7c), GLUT1 protein remained unaffected in all three
cell types (Fig. 7b) underscoring drug’s targeting specificity.The differential expression profiles of GLUT (protein and
gene) (Fig. 7b-c), and Rab (Additional file 5: Figure S5A),
family members likely reflect the distinct glycolytic require-
ments of RT4, T24 and T24-X cells for survival and growth.
3-BrPA induces splicing silencing of GLUT4 RNA in bladder
cancer cells
Through the utilization of GLUT4 exon- and intron-specific
primers (Additional file 5: Figure S5B and Additional file 9:
Table S1) in RT-sqPCR protocols, 3-BrPA proved capable to
suppress splicing functions that specifically control GLUT4
RNA maturation, in all three cell types examined. The dose-
driven formation of high MW exonic fragments, which
could retain their in-between introns, revealed drug’s profi-
ciency to inhibit spliceosome activities in a GLUT4-specific
manner (Fig. 7d-e). Sequence analysis of Ex7-Ex8 (411 bp)
and Ex9-Ex10 (336 bp) products corroborated the retention
of respective introns and generation of unspliced GLUT4
RNA transcripts (Additional file 5: Figure S5C). From the
plethora of genes examined in T24, only GLUT4 presented
with strong phenotypes of splicing silencing, throughout its
transcript, in response to 3-BrPA, whereas the rest ones
remained either unaffected or followed gene-specific down-
regulation patterns (Additional file 6: Figure S6). However,
G6PD, previously reported to undergo exon 12-mediated
splicing inhibition [56], and MCT1, a main determinant of
3-BrPA sensitivity [57], were subjected to weak 3-BrPA-
directed aberrant splicing, exclusively in susceptible cells
(Additional file 7: Figure S7A-B). Remarkably, FasL was the
only gene shown to be strongly upregulated in 3-BrPA-
treated T24 cells (Fig. 7f), thus indicating engagement of
FasL-orchestrated death [17, 21, 22]. The abilities of Taxol
and Doxorubicin to specifically induce the unspliced GLUT4
(and irregular G6PD) RNA and its spliced mature form,
respectively (Fig. 7f and Additional file 7: Figure S7C),
underscore the complexity of network that controls glucose
homeostasis-related gene expression in T24 upon cellular
stress.
Sensitivity of bladder cancer cells to 3-BrPA relies on MCT, but
not MPC, family members and macropinocytosis functions
The structural resemblance of 3-BrPA to pyruvate and lac-
tate [12, 58] impelled us to examine the contribution of
MCT1, MCT4 and SMCT1 plasma-membrane monocar-
boxylate transporters [59, 60], as well as MPC1 and MPC2
mitochondrial pyruvate carrier components [61], to bladder
Fig. 5 (See legend on next page.)
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Fig. 5 Aberrant activities of Akt and p44/42 MAPK signaling pathways critically modulate bladder cancer cell sensitivity to 3-BrPA. (a-b) Representative
(three independent experiments) Western blotting profiles of whole-cell protein extracts derived from T24 cells, grown at ~60 % confluency and treated
with the indicated doses of 3-BrPA for 24 h, in the absence or presence (pre-incubation for 2 h) of 100 μM LY294002 (a) or 100 μM U0126 (b). The proteins
examined were p-Akt-Ser473, Akt (a), p-p44/42 MAPK-Thr202/Tyr204 and p44/42 MAPK (b), while Actin was used as molecule of reference. Brackets and
asterisks denote the high MW forms of Akt (a) and p44/42 MAPK (b) kinases. (c-e) MTT cytotoxicity assays of T24 cells, seeded at low confluency and
exposed to the indicated doses of 3-BrPA for 24 h, in the absence or presence (pre-incubation for 2 h) of 100 μM LY294002 (c), 100 μM U0126 (d) and
1 mM AICAR (e). LY294002, U0126 and AICAR remained in the growth medium with half of their initial respective concentrations for 24 h more, post-
pre-incubation. Stock solutions for all three reagents (LY294002, U0126 and AICAR) were prepared in DMSO. MTT viability rates obtained from
the cocktail of 3-BrPA with each kinase inhibitor (LY294002 and U0126), or activator (AICAR), were compared to the respective ones of 3-BrPA alone
and, after their normalization with values derived from inhibitor/activator only, versus its cognate solvent, they were presented in fold (x) of inhibitor/
activator-induced cell survival increase. (c-e) Data are reported as mean ± standard deviation of triplicates of three independent experiments. *P< 0.001.
(f-g) MTT cytotoxicity assays of RT112 (f) and TCCSUP (g) cells, grown at ~60 % confluency and treated with the indicated doses of 3-BrPA for 24 h (also,
see Additional file 10: Table S2). (f-g) Results are denoted as mean ± standard deviation of triplicates of, at least, three independent experiments. *P< 0.001
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MCT1 and SMCT1 in T24 indicated their roles as high-
affinity importers of 3-BrPA, reinforcing previous reports in
different tumorigenic environments [57, 62], while upregu-
lated levels of MCT4 in RT4 dictated its ability to function
as high-efficiency exporter of 3-BrPA that was freely
diffused into tumor cells (Fig. 8a-b). Alternatively, MCT4
could operate as low-affinity 3-BrPA importer [63], result-
ing in limited harm of only few drug targets and, therefore,
preserving RT4 survival and growth. Interestingly, the
cellular contents of MPC family members proved to be
strongly diminished in T24 (compared to RT4) (Fig. 8a),
thus uncoupling MPC activities from 3-BrPA-mediated
cytotoxicity. Attenuation of MPC complex likely contrib-
utes to acquisition of Warburg effect-like glycolytic features
and metabolic reprogramming of bladder cancer cells.
MPC pharmacological inhibition through employment of
UK-5099 suitable concentrations [61, 64] proved unable to
salvage T24 (Fig. 8c), hence corroborating the MPC-
independent susceptibility of T24 to 3-BrPA. Remarkably,
AR-C155858, a potent MCT1 inhibitor [65], could provide
T24 cells with a striking survival advantage against drug’s
cytotoxic power (Fig. 8d), rendering MCT1 a critical deter-
minant of 3-BrPA uptake and principal regulator of bladder
cancer cell sensitivity to 3-BrPA. The relatively unharmed
SMCT1 carrier could compensate for the dose-specific
reduced expression of MCT1 in T24 (Fig. 8a-b), while,
alternatively, 3-BrPA quick mode of action (Fig. 1c) could
likely reflect drug’s massive cellular influx prior to the
detrimental targeting of its (3-BrPA) cognate importers.
Despite the T24-specific expression of MCT1, its dose-
dependent downregulation in response to the drug (Fig. 8a-b)
implies the operation, besides SMCT1 [62], of an add-
itional 3-BrPA transportation system. Since (a) oncogenic
Ras-transformed cells (e.g. T24) require macropinocytosis
(upon glutamine deprivation) for proliferation and growth
[66], (b) pharmacological inhibition of PI3K (e.g. Fig. 5)
prevents macropinosome closure [67], and (c) activated
Akt and p44/42 MAPK (e.g. Fig. 4) stimulate phosphoryl-
ation and activation of NHE1 [68, 69], a critical determin-
ant of macropinocytosis [67], the entry of 3-BrPA in T24cells could be likely regulated by macropinocytosis. Hence,
we employed EIPA, a bona fide NHE1 and macropinocyto-
sis inhibitor [66, 67, 70], to provide T24 cells with a survival
advantage against 3-BrPA cytotoxic power. It proved that
EIPA could strikingly rescue the 3-BrPA-treated T24 cells
(Fig. 8e), thus indicating the essential contribution of
macropinocytosis route to 3-BrPA uptake and toxicity.
Altogether, we reveal that MCT1 and macropinocytosis
activities are critically implicated in 3-BrPA-induced death
of T24 cells.
Discussion
Despite the pioneer chemotherapeutic strides made in other
malignancies, no major breakthroughs have been achieved in
the treatment of urothelial bladder carcinoma, with cisplatin
remaining the only cornerstone for its clinical management
in the past three decades. However, acquisition of resistance
to cisplatin and emergence of systemic toxicity severely limit
remedy’s success, ultimately resulting in failure of long-term
disease remission and threat to patients’ survival [71]. There-
fore, there is an urgent need to develop more effective and
less toxic regimens for bladder cancer therapy.
To this direction, and by exploiting the metabolic switch
of cancer cells from mitochondrial oxidative phosphoryl-
ation to aerobic glycolysis (Warburg effect), we have herein
attempted to target bladder cancer cells with 3-BrPA, a
previously reported inhibitor of glycolysis. Since T24, but
not RT4, cells carry activated -oncogenic- Ras, increased
PI3K/Akt signaling, mutant p53 and mitochondrial defects
(MPC repression), critical features for glycolytic fueling
[7, 9, 72], it seems that they (T24) significantly rely on
Warburg effect-like metabolism to support their energy
demands and rapid cell divisions. Although 3-BrPA has
been previously used for targeting several types of can-
cer cells [10, 11, 73], it has never been, so far, employed
for bladder cancer treatment. Despite its initial view as a
specific inhibitor of glycolysis [12–16], we herein demon-
strate that 3-BrPA can severely perturb the integrity of
genome, transcriptome (including splicing), proteome
(including glycolytic regulators) and kinome of T24 (and
T24-X) cells, in a gene/transcript/protein/kinase-specific
Fig. 6 (See legend on next page.)
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Fig. 6 B-RafV600E and K-RasG13D oncogenic proteins are not associated with 3-BrPA-induced or glucose deprivation-driven death of bladder cancer
cells. (a) DNA sequencing chromatograms (three independent experiments) of B-Raf (left panel) and K-Ras (right panel) genomic PCR products
amplified from RT4, T24 and T24-X cells, using gene-specific primers flanking the V600 and G12/G13 cognate codons, respectively (also, see
Additional file 4: Figure S4, Additional file 9: Table S1 and Additional file 10: Table S2). F/R: forward/reverse -DNA sequence- reading direction.
(b-f) MTT cytotoxicity assays of RT4 (b), T24 (c), T24-X (d), RT112 (e) and TCCSUP (f) cells, grown at ~60 % confluency in glucose-free 1X DMEM
complete medium (containing 10 % FBS, 2 mM L-glutamine, 1 mM sodium pyruvate, 50 mM sodium bicarbonate, 1X non-essential amino acids, 100 u/ml
penicillin and 100 μg/ml streptomycin), and harvested for further processing at the indicated time points (days) (also, see Additional file 10: Table S2). (b-f)
Data are reported as mean ± standard deviation of triplicates of three independent experiments. *P< 0.001
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elimination at the preclinical level. Besides its potency
to generate DNA breaks, 3-BrPA proved able to harshly
harm the transcription machinery in a gene-specific man-
ner. In contrast to their vast majority, only few of the ex-
amined genes remained unaffected, with FasL being the
sole upregulated one in response to 3-BrPA. Moreover,
none of them, except GLUT4, presented with strong
splicing silencing features, after exposure to 3-BrPA, in-
dicating drug’s power to impair spliceosome machinery
in a transcript-dependent fashion (Fig. 7, Additional
file 5: Figure S5, Additional file 6: Figure S6 and Additional
file 7: Figure S7).
To the same direction, our data support the notion
that 3-BrPA is not just a conventional alkylating factor
that promiscuously attacks cysteine residues in proteins
[12, 15, 57], but rather a powerful and multifaceted che-
motherapeutic agent that strongly pyruvylates its target
proteins in a highly specific and selective manner. In toto, 3-
BrPA proved capable to (a) severely inhibit phosphorylation-
dependent signaling activities (e.g. Akt), (b) reduce total
protein cellular contents (e.g. LC3B), (c) impose protein
structural fragmentations (e.g. PARP), (d) promote pro-
tein post-translational modifications (e.g. pyruvylation;
HK2), (e) upregulate typical (e.g. H2A.X) and aberrant
phosphorylation-mediated signaling (e.g. 47 and 39 kDa),
and (f ) alter splicing patterns of selected signaling de-
terminants (e.g. 47 kDa), following dose-, cell type- and
protein-dependent modes. 3-BrPA can target proteins
for pyruvylation and induce depletion of cellular ATP,
hence harming and/or eliminating the respective phos-
phorylated forms and cognate activities (Figs. 2 and 4, and
Additional file 2: Figure S2). Nevertheless, the production
of 47 and 39 kDa phosphorylated kinases (Fig. 4), and the
induction of FasL gene (Fig. 7), in response to 3-BrPA,
suggest that affected cells preserve marginal ATP levels to
successfully encounter the bioenergetic expenses of regu-
lated necrosis.
Drug-directed severe dysfunction of their kinome and
selective collapse of their proteome compel T24 (and
T24-X), but not RT4, cells to undergo apoptotic and reg-
ulated necrotic death in a dose-specific manner. The two
major issues we were challenged to herein resolve regarded
the molecular signatures that control bladder cancer cellsensitivity to 3-BrPA and the molecular mechanisms that
orchestrate T24 necrotic demise. In terms of the first issue,
mutant p53, oncogenic Ras, constitutive autophagy, ab-
errant PI3K/Akt, p44/42 MAPK and AMPKα signaling,
together with differential expression of MCT and MPC
family members were examined. Surprisingly, despite the
drug-induced genotoxicity, 3-BrPA proved unable to phos-
phorylate and activate the either -endogenously expressed-
mutant (ΔY126) or -transiently transfected- wild-type p53
form in T24, while cells could not be rescued from the
drug in the presence of functional (responsive to Doxo-
rubicin) wild-type p53 protein. Moreover, 3-BrPA could
not transcriptionally induce any of the p53 bona fide
target genes examined. However, 3-BrPA and PRIMA-1
could strongly synergize to specifically eradicate the
mutant p53-carrying T24 and T24-X cells (Fig. 3), there-
fore shaping a novel and promising preclinical platform
for bladder cancer therapy. In contrast to its dispensable
role in 3-BrPA-induced death of bladder cancer cells,
p53 was recently associated with susceptibility of breast
cancer cells to 3-BrPA [74], thus indicating the malignant
environment-dependent engagement of p53 in drug’s
cytotoxic activities.
Since B-RafV600E or K-RasG13D oncogenic mutations were
previously reported to favor the successful targeting of
3-BrPA to colon cancer cells [51], their involvement in
bladder cancer cells’ differential sensitivity to the drug
was herein examined. Interestingly, all five cell lines pre-
sented with wild-type B-RafV600 and K-RasG13 gene profiles,
hence implicating a role of distinct aberrant determinants,
such as PIK3CAE545K (TCCSUP) and H-RasG12V (T24).
Indeed, the H-RasG12V oncogenic mutation in T24 pro-
vides cells with strong constitutive autophagy (Fig. 2)
and high basal levels of PI3K/Akt and MAPK (p44/42
and p38) signaling (Fig. 4). Given that T24 cells require
H-RasG12V-dependent autophagy for growth and survival
[32], the 3-BrPA-orchestrated suppression of autophagy
(Fig. 2) must critically contribute to 3-BrPA-treated T24
and T24-X necrotic death. Autophagy deficiency likely in-
creases the cellular load of abnormal mitochondria and
limits ATP availability, while the combined inactivation of
apoptosis and autophagy may promote necrosis, drastic-
ally restricting tumor growth [31, 75]. Therefore, in con-
trast to previous reports in hepatocellular carcinoma and
Fig. 7 (See legend on next page.)
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Fig. 7 Critical regulators of glucose homeostasis are detrimentally targeted after bladder cancer cell exposure to 3-BrPA: drug-induced splicing
silencing of GLUT4 RNA. (a-b) Representative (three independent experiments) Western blotting profiles of whole-cell protein extracts obtained
from RT4, T24 and T24-X cells, seeded at ~60 % confluency and exposed to the indicated doses of 3-BrPA for 24 h. The proteins examined were HK2,
GAPDH, p-AS160-Thr642, AS160, Rab10, Tug (a), GLUT1 and GLUT4 (b), while Actin was used as molecule of reference. (c-f) Gene expression profiles, as
evidenced through employment of RT-sqPCR protocols (three independent experiments), using total RNA preparations derived from RT4, T24
and T24-X cells, grown at ~60 % confluency and treated with the indicated doses of 3-BrPA (c-f), Taxol and Doxorubicin (f) for 24 h (also, see
Additional file 5: Figure S5, Additional file 6: Figure S6 and Additional file 7: Figure S7). Besides the oligonucleotide primers able to specifically
recognize the GLUT1, GLUT2, GLUT3 (c) and FasL (f) genes, GLUT4-specific primers were used to amplify several exon-exon (e.g. Ex7-Ex8), exon-intron
(e.g. Ex4-In4/5) and intra-intronic (e.g. In2/3) segments of the two major RNA splicing variants examined (http://www.ensembl.org/Homo_sapiens) (d-f)
(also, see Additional file 5: Figure S5 and Additional file 9: Table S1). GAPDH served as gene of reference. Ex: (single) exon. In: intron (in-between successive
exons). Sv001/Sv004: GLUT4 RNA splicing variants
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not its upregulation, that drives bladder cancer cells to
ATP depletion-mediated death. Similarly to colon car-
cinoma [51], resistance of bladder cancer cells to 3-BrPA
was conversely associated with their tolerance to glu-
cose deprivation (Figs. 1, 5 and 6, and Additional file
10: Table S2), again uncoupling B-RafV600E and K-
RasG13D oncogenic mutations from bladder cancer cell
survival in hypoglycemic environments. However, upon
glucose lack, the T24-specific and H-RasG12V-driven con-
stitutive autophagy could recycle intracellular components
to satisfy pivotal metabolic requirements, hence promoting
survival and tolerance to bioenergetic stress.
Besides constitutive autophagy, T24 cells are also addicted
to strong basal activities of Akt signaling (Fig. 4). Since
HK2 enhances autophagy upon glucose starvation [42],
preserves mitochondrial integrity through its (HK2) Akt-
mediated phosphorylation [38] and supports oncogenic
K-Ras-directed tumorigenesis [52], we reason that 3-BrPA
preferably targets the -mitochondrial- HK2 phosphory-
lated form. Therefore, its -putative- constitutive phos-
phorylation by activated Akt (inhibited by LY294002) in
T24 may render -mitochondrial- HK2 vulnerable to 3-BrPA,
whereas the non-phosphorylated -cytosolic- form in RT4
cannot be recognized by the drug. Indeed, the dose-
dependent induction of a 145 kDa protein directly re-
flects the T24-specific targeting of 3-BrPA to HK2,
through most likely a pyruvylation process (Fig. 7). 3-
BrPA might promote the dissociation of -phosphorylated-
HK2 from mitochondria in T24, as previously shown in
leukemia and hepatocellular carcinoma cells [15, 16].
In accordance with several reports [15, 16, 38, 78, 79],
HK2-mitochondria disruption could presumably impair
mitochondrial integrity, propelling death of T24, but not
RT4, cells.
In addition to HK2 targeting, 3-BrPA proved able to
drastically downregulate several determinants of glucose
homeostasis in T24 and T24-X, with GAPDH and HK2
exhibiting intriguingly distinct expression profiles in re-
sponse to the drug (Fig. 7). The 3-BrPA-induced -severe-
reduction of GAPDH, but not HK2, cellular contents in
T24 (and T24-X) can be associated with drug’s potency tostrongly inhibit GAPDH, but not HK2, glycolytic activity
in hepatocellular carcinoma cells [13, 14]. Overall, 3-BrPA
could promote, in T24, (a) a pyruvylation-mediated re-
lease of phosphorylated HK2 from mitochondria, with-
out directly affecting its enzymatic activity, and (b) a
structural elimination of GAPDH, likely through pro-
tein degradation, which together with injury of Rab10,
Tug and GLUT4 could cause a detrimental bioenergetic
crisis (Fig. 2 and Additional file 2: Figure S2).
LY294002 (PI3K/Akt inhibitor), U0126 [MAPKK(1/2)/
MAPK(p44/42) inhibitor] and AICAR (AMPK agonist)
could salvage, albeit at different levels each, T24 cells
from 3-BrPA cytotoxic power (Fig. 5). Since Akt and
p44/42 MAPK have been previously implicated in NHE1
phosphorylation and activation [68, 69], and NHE1 repre-
sents a bona fide target of EIPA [67, 70], whose adminis-
tration strikingly rescues T24 from 3-BrPA (Fig. 8), we
herein reason that LY294002 and U0126 implement their
beneficial roles in cell survival via attenuation of Akt- or
p44/42 MAPK-dependent NHE1 activity (see below). In
contrast to LY294002, U0126 and AICAR, the MCT1-spe-
cific inhibitor AR-C155858 [65] presented with a unique
proficiency to completely, and not just partly, rescue T24
from 3-BrPA (Fig. 8), thus underscoring the predominant
contribution of MCT1-mediated drug influx to bladder
cancer cell responsiveness to 3-BrPA. Apparently, the two
MPC family members examined cannot offer any kind of
3-BrPA trafficking in T24 (Fig. 8), while in RT4 they likely
allow the entry of pyruvate into functional mitochondria.
Besides MCT1, the T24-specific expression pattern of
SMCT1 agrees for its role as another major 3-BrPA im-
porter in bladder cancer cells (Fig. 8). Furthermore, provid-
ing that MCT4 functions as drug exporter, its significantly
reduced contents in T24 (Fig. 8) could likely enhance the
MCT1-mediated accumulation of 3-BrPA in T24. Intri-
guingly, and despite their tolerance to 3-BrPA (Fig. 1), RT4
cells presented with notable downregulation of SAPK/JNK,
GAPDH and Tug proteins (Figs. 4 and 7) and strong up-
regulation of unspliced GLUT4 transcripts (Fig. 7). There-
fore, it may be either the free, but slow, diffusion of 3-BrPA
[60], or the ability of MCT4 to import the drug [63], with
low affinity and rate, that specifically operates in RT4
Fig. 8 (See legend on next page.)
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Fig. 8 MCT family-member and macropinocytosis activities critically regulate bladder cancer cell susceptibility to 3-BrPA - the dispensable role of
MPC components. (a) Representative (three independent experiments) Western blotting profiles of whole-cell protein extracts obtained from RT4
and T24 cells, seeded at ~60 % confluency and treated with the indicated doses of 3-BrPA for 24 h. The proteins examined were MCT1, MCT4,
SMCT1, MPC1 and MPC2, while Actin was used as molecule of reference. (b) Representative (three independent experiments) immunofluorescence
images of MCT1 expression and localization in RT4 and T24 cells, seeded at ~60 % confluency and exposed to the indicated doses of 3-BrPA for 4 h
(also, see Fig. 1c). Scale bars: 3 μm. (c-e) MTT cytotoxicity assays of T24 cells, grown at low (and ~60 %; data not shown) confluency and treated with
the indicated doses of 3-BrPA for 24 h, in the absence or presence (pre-incubation for the denoted time) of 1 or 10 μM UK-5099 (c), 0.1 or
1 μM AR-C155858 (d) and 10 or 50 μM EIPA (e) (both low and ~60 % confluency allowed the striking survival of 3-BrPA-treated T24 cells
grown in the presence of either AR-C155858 or EIPA, but not UK-5099, inhibitor). Each inhibitor remained in the growth medium with half of
its initial respective concentration(s) for 24 h more, post-pre-incubation. Survival rates of each cocktail (3-BrPA plus inhibitor) were normalized
according to the respective values of inhibitor only. Stock solutions of all three inhibitors (UK-5099, AR-C155858 and EIPA) (c-e) were prepared
in DMSO. Pre-incubation (for 1.5 h) of T24 with 100 μM EIPA proved significantly detrimental for the cells (data not shown). (c-e) Results are
reported as mean ± standard deviation of triplicates of three independent experiments. *P < 0.001
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below a certain threshold and only few sensitive targets
can be affected, such as GAPDH and GLUT4-specific spli-
ceosomal components, without, however, perturbing
cell growth and survival. Altogether, and in accordance
with previous reports in different cellular settings [57, 62],
we conclude that MCT family members undoubtedly con-
trol the uptake of 3-BrPA by bladder cancer cells and critic-
ally modulate their sensitivity to the drug.
Strikingly, in addition to MCT1, NHE1-mediated macro-
pinocytosis proved also essential for 3-BrPA-induced cyto-
toxicity in T24 (Fig. 8). Since AR-C155858 and EIPA are
both able to completely, and not just partly, salvage T24
from 3-BrPA (Fig. 8), we reason that their respective mo-
lecular targets, MCT1 and NHE1 [65, 67, 70], must control
cell sensitivity and death, in response to the drug, in a
highly concerted and inter-dependent fashion. Hence,
we propose that MCT1 and NHE1 could require each
other for optimal activity. During the H-RasG12V-driven
and NHE1-dependent macropinocytotic entry of 3-BrPA
in T24 (an EIPA-inhibited process; Fig. 8), NHE1 likely
exchanges intracellular H+ with extracellular Na+ ions.
Providing that MCT1 and NHE1 share the same mem-
brane micro-domain that orchestrates macropinocytosis,
the NHE1-mediated enrichment of extracellular micro-
environment with H+ could strongly facilitate the coupled
and simultaneous reverse transport of H+ with 3-BrPA
from the acidified extracellular micro-space into T24 cells
through engagement of MCT1 carrier (an AR-C155858-
inhibited process; Fig. 8). Now, the imported H+ could be
efficiently exported again through H+-regulated activation
of NHE1 [80, 81], thus maintaining the functional in-
tegrity of macropinocytosis machinery in T24. In toto,
it seems that 3-BrPA can enter T24 via the two inter-
dependent routes of MCT1 transporter and NHE1-
mediated macropinocytosis.
Entry of 3-BrPA in T24 is followed by quick induction
of dose-specific cell death. Pharmacological interventions
indicated the critical roles of PARP- and MLKL/Drp1-
mediated necrotic axes, together with a novel Nec-7-targeted pathway (Fig. 2). Low drug dose activates
caspase-dependent apoptosis, featured by typically cleaved
PARP (and Lamin A/C), whereas high drug doses force
T24 to non-caspase-mediated death, characterized by ir-
regular PARP (and Lamin A/C) cleavage profiles. This and
the ability of PARP inhibitor PJ-34 [18, 20] to significantly
rescue 3-BrPA-treated T24 and T24-X (Fig. 2) provide evi-
dence for implication of PARP over-activation in drug-
orchestrated cell death. 3-BrPA-induced genotoxic stress
(Fig. 3), together with the rather aberrant signaling func-
tions of 47 (inhibited by U0126) and 39 kDa novel forms
(Fig. 4) could cause uncontrolled PARP activity. Indeed,
maximal or sustained activation of PARP requires its
direct phosphorylation by p44/42 MAPK or JNK1 kinase,
respectively, under cellular stress [20, 82–84]. 3-BrPA-
driven over-activated PARP extensively consumes NAD+
pools, which together with suppressed autophagy and
collapsed glycolysis (Figs. 2 and 7) result in detrimental
depletion of ATP stores and, finally, necrotic death of
T24 (and T24-X) (Figs. 1–2 and Additional file 2: Figure
S2). Bioenergetic stress can be alleviated by AICAR-
mediated activation of AMPK metabolic sensor and subse-
quent replenishment of ATP and NADPH pools (Fig. 5)
[43, 85]. PARP can also mediate caspase-independent cell
death by triggering translocation of AIF from mitochondria
to nucleus, where it (AIF) promotes large-scale chromati-
nolysis [18–21, 84, 86]. However, and in contrast to a previ-
ous report in hepatoma cells [87], we were unable to detect
transport of AIF from cytoplasm (presumably mitochon-
dria) to nucleus upon exposure of T24 to 3-BrPA. Further-
more, T24 cells presented with significantly reduced
AIF cellular content after their exposure to necrotic
drug doses (Additional file 8: Figure S8A-C).
Pharmacological intervention in the other two funda-
mental necrotic routes RIPK1/MLKL/Drp1 and p53/CypD
proved the dispensable roles of RIPK1 (targeted by Nec-1
and Nec-5) [19, 21–25] and CypD (targeted by CsA) [28]
mediators in 3-BrPA-driven death of T24 (Fig. 2). Neither
p53 (Fig. 3) nor CypD (Fig. 2) can essentially direct cyto-
toxicity of 3-BrPA in T24, therefore uncoupling p53/
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mitochondrial PTPC opening) from drug-induced regu-
lated necrosis of bladder cancer cells. However, the ability
of NSA, a bona fide human MLKL inhibitor [22–24], to
provide cells with a strong survival advantage against
3-BrPA (Fig. 2) clearly indicates engagement of novel
necrotic pathways that orchestrate regulated necrosis
of 3-BrPA-treated T24 cells in RIPK1-independent but
RIPK3/MLKL-dependent manner. Indeed, in contrast to
RIPK3 (when elevated), RIPK1 does not seem to have an
obligatory role in necroptosis (challenged by TNF) signal-
ing [88], while catalytically active RIPK3 can mainly cause
MLKL-mediated necroptotic death in RIPK1-deficient
environment of mouse embryonic fibroblasts [89]. Most
interestingly, via employment of chemically enforced
dimerization systems, it proved that -artificial- homodi-
merization or oligomerization of RIPK3 cannot only
eliminate reliance on RIPK1 but is also sufficient to trigger
MLKL-dependent necroptosis [90, 91]. Accordingly, by
exploiting its selective alkylating capacity, 3-BrPA could
promote, in T24 cells, the homodi(oligo)merization and
sequential (auto)phosphorylation-dependent activation
of RIPK3 that induces phosphorylation-driven recruitment
of MLKL to the activated necrosome [22, 23]. Now,
MLKL may be licensed to orchestrate the downstream
(potentially interrelated) necrotic routes of Drp1-mediated
mitochondrial fragmentation [24] and TRPM7-directed
Ca2+ influx [92], both likely contributing to T24 regulated
necrosis in response to 3-BrPA. The abilities of NSA and
Mdivi-1 to significantly rescue T24 cells from 3-BrPA
(Fig. 2) render MLKL and Drp1 major determinants of
drug’s cytotoxicity in bladder carcinoma.
During necroptosis, phosphorylated MLKL forms tri-
mers that translocate to plasma membrane to promote
TRPM7-dependent entry of Ca2+ ions [92]. Alternatively,
necroptosis execution can be mediated by translocation
of MLKL tetramers to plasma membrane, consequent in-
flux of Na+ ions and, eventually, membrane rupture due
to increased osmotic pressure [93]. Remarkably, the bona
fide target of EIPA, which (EIPA) strikingly salvages T24
from 3-BrPA (Fig. 8), is the principal Na+/H+ exchanger
NHE1 [67, 70]. Hence, 3-BrPA-induced oligomerization of
MLKL might direct translocation of the protein to plasma
membrane, wherein it facilitates NHE1-mediated influx of
Na+ ions. Now, upon EIPA administration in T24, NHE1
is inhibited, Na+ entry is impaired, osmotic stress is
prohibited, plasma-membrane integrity is preserved and
cells are, finally, protected from necrotic power of 3-BrPA
(Fig. 8). It seems that NHE1 may direct not only the early
(macropinocytosis) but also the late (osmotic pressure
and membrane damage) stages of regulated necrosis in
3-BrPA-treated T24 cells.
Another route of RIPK-mediated necroptosis has proved
to implicate p44/42 MAPK and SAPK/JNK signaling thatpropels AP-1-dependent activation of TNFα gene [47, 94].
Given that FasL gene requires SAPK/JNK-driven engage-
ment of AP-1 for its (FasL) transcriptional induction [95],
a novel necrotic axis of RIPK3/SAPK/JNK might also
operate in 3-BrPA-treated T24 cells. 3-BrPA-directed
stimulation of RIPK3 could promote aberrant SAPK/JNK
signaling (39 kDa; Fig. 4), sequentially targeting down-
stream AP-1-dependent activation of FasL gene in T24
upon drug exposure (Fig. 7). Now, membrane-anchored
or secreted FasL protein can amplify necrotic signaling via
a positive feedback loop.
In toto, we herein demonstrate, for the first time, that
3-BrPA can be successfully employed to eradicate, at the
preclinical level, human bladder cancer cells with highly
oncogenic molecular signatures, thus underscoring drug’s
potential to be embodied in the clinical practice for dis-
ease therapy, either as single agent or in cocktail regimens.
Its strong cytotoxic synergism with PRIMA-1 foreshadows
the development of 3-BrPA-based new protocols with po-
tent chemotherapeutic capacity against urothelial bladder
malignancies.
Conclusions
3-BrPA seems to selectively target high-grade bladder
cancer cells that are addicted to oncogenic H-Ras, con-
stitutive autophagy, aberrant PI3K/Akt/MAPK signaling
and MCT1/NHE1 “pumping” activity, and can also tol-
erate lack of glucose for normal growth and survival.
However, p53, B-RafV600E and K-RasG13D proved dispens-
able for drug’s cytotoxic activity, thus rendering 3-BrPA a
powerful therapeutic tool for the successful management
of urothelial bladder tumors carrying either wild-type or
mutant p53, B-Raf or K-Ras oncogenic forms. To the con-
trary, MCT1 and NHE1 plasma-membrane pumps are
both required for elimination of 3-BrPA-treated bladder
cancer cells. Hence, Ras, autophagy, Akt, MAPK, MCT1
and NHE1 represent critical molecular signatures for
cellular sensitivity of bladder cancer to 3-BrPA (Fig. 9).
After its MCT1- and NHE1-directed entry in oncogenic
H-Ras-transformed bladder cancer cells, 3-BrPA activates
the PARP and RIPK3/MLKL/Drp1 necrotic axes, pre-
sumably together with the RIPK3/MLKL/TRPM7, RIPK3/
MLKL/NHE1 and RIPK3/SAPK/JNK necrotic subroutines,
in RIPK1-independent manner. Furthermore, a Nec-7-
targeted novel necrotic pathway remarkably contributes
to drug’s ability to kill bladder cancer cells. However, the
p53/CypD/PTPC distinct necrotic subroutine [28, 29]
cannot be engaged in 3-BrPA-induced regulated necrosis
of bladder cancer cells, thus unveiling drug’s proficiency
to mobilize necrotic pathways in a highly specific manner
(Fig. 9).
To our knowledge, this is the first preclinical study
having -thoroughly- examined 3-BrPA as a highly
promising chemotherapeutic agent in urothelial bladder
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-interrelated- cytotoxic routes are dissected not in miscel-
laneous biological systems but in a solely one cellular
platform being insulted by 3-BrPA. Our experimental
endeavors to illuminate the cytotoxic signatures of 3-BrPA
and its “deathome” dynamics in human bladder cancer re-
vealed drug’s ability to trigger dose-dependent apoptosis and
regulated necrosis, and -severely- derange autophagic, signal-
ing, metabolic, splicing and transcriptional integrity of blad-
der cancer cells, compelling them to rapid and harsh death
(Fig. 9). It must be this multifaceted power of 3-BrPA to se-
lectively target numerous determinants of cellular physiology
that needs to be suitably exploited for successful chemother-
apeutic management of urothelial bladder malignancies.
Methods
Drugs, reagents and chemicals
3-BrPA, PJ-34, Nec-1, Nec-5, Nec-7, Mdivi-1, CsA and
UK-5099 were obtained from Sigma-Aldrich (Missouri,Fig. 9 Flow-chart depicting the 3-BrPA-emanated, dose-dependent cytotox
associations between the denoted responses, while straight lines indicate the
interrelations in T24 cellsUSA). NSA and PRIMA-1 were provided by Merck
Millipore-Calbiochem (Merck KGaA, Darmstadt, Germany).
LY294002, U0126 and AICAR were supplied by Cell Signal-
ing Technology Inc. (Massachusetts, USA). Nec-1 (besides
Sigma-Aldrich reagent) and EIPA were purchased from
Santa Cruz Biotechnology Inc. (Texas, USA). AR-C155858
was provided by AdooQ BioScience (California, USA).
Doxorubicin was obtained from EBEWE Arzneimittel
GmbH (Unterach, Austria), while Taxol was supplied
by Bristol-Myers Squibb (New York, USA). Rabbit poly-
clonal antibodies against Caspase-3, Caspase-9, PARP,
Lamin A/C, Atg5, Atg7, Atg12, Beclin-1, LC3B, Akt, p-
Akt-Ser473, FoxO1, p-FoxO1-Thr24/p-FoxO3a-Thr32, GSK-3α,
p-GSK-3α/β-Ser21/9, p44/42 MAPK, p-p44/42 MAPK-Thr202/
Tyr204, p38 MAPK, p-p38 MAPK-Thr180/Tyr182, SAPK/
JNK, p-SAPK/JNK-Thr183/Tyr185, mTOR, p-mTOR-Ser2448,
AMPKα, p-AMPKα1-Ser485/p-AMPKα2-Ser491, p53,
p-p53-Ser15, p-p53-Ser392, H2A.X, p-H2A.X-Ser139,
p-AS160-Thr642, Rab10, Tug and Actin (Pan-Actin)ic pathways in bladder cancer cells. Dash lines represent presumable
herein revealed 3-BrPA-orchestrated cytotoxic routes and their functional
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(Massachusetts, USA). Rabbit monoclonal antibodies
against p-Akt-Thr308, GSK-3β, p-GSK-3β-Ser9, S6, p-
S6-Ser235/236, p-AMPKα-Thr172, HK2 and AS160 were ob-
tained from Cell Signaling Technology Inc. (Massachusetts,
USA). Rabbit polyclonal antibodies recognizing ICAD,
GAPDH and GLUT1 were supplied by Santa Cruz Bio-
technology Inc. (Texas, USA). Mouse monoclonal antibody
against Caspase-8 was provided by Cell Signaling Tech-
nology Inc. (Massachusetts, USA). Mouse monoclonal
antibody against GLUT4 was obtained from Santa Cruz
Biotechnology Inc. (Texas, USA). Rabbit polyclonal anti-
bodies recognizing MCT1 and MCT4 were supplied by
Merck Millipore (Merck KGaA, Darmstadt, Germany).
Rabbit polyclonal antibodies against SMCT1 and MPC1
were purchased from Novus Biologicals LLC (Connecti-
cut, USA). Rabbit polyclonal antibody recognizing MPC2
was provided by Proteintech Group Inc. (Illinois, USA).
Anti-rabbit IgG-HRP and anti-mouse IgG-HRP second-
ary antibodies used in Western blotting were supplied by
Sigma-Aldrich (Missouri, USA). Anti-rabbit IgG-DyLight®
488 secondary antibody used in immunofluorescence was
obtained from Thermo Fisher Scientific Inc. (Massachusetts,
USA). ECL Western blotting reagents were purchased from
GE Healthcare Life Sciences-Amersham (Buckinghamshire,
England). Gene-specific oligonucleotide primers were syn-
thesized by Metabion (Steinkirchen, Germany) and Eurofins
Genomics-Operon Biotechnologies (Alabama, USA). All
other chemicals were provided by Sigma-Aldrich (Missouri,
USA) and AppliChem GmbH (Darmstadt, Germany).
Cell lines and culture conditions
The RT4, RT112, T24 and TCCSUP human cell lines used
herein have been generated from urothelial carcinomas of
the bladder. RT4 cells were obtained from ECACC-Sigma-
Aldrich (Missouri, USA), while RT112 cells were kindly
provided by Professor John R. Masters (London, England).
T24 and TCCSUP cells originated from ATCC-LGC
Standards GmbH (Wesel, Germany). T24-X cells derived
from T24-specific tumor xenografts, sequentially created
in SCID mice (Additional file 1: Figure S1). Cell cultures
were grown in complete DMEM medium, supplemented
with 10 % FBS, at 37 °C and 5 % CO2. DMEM with no
glucose (glucose-free) was purchased from Thermo Fisher
Scientific Inc.-Life Technologies™-Gibco® (Massachusetts,
USA). All other cell culture media and reagents were
supplied by Merck Millipore-Biochrom AG (Merck KGaA,
Darmstadt, Germany).
Cell viability MTT assays
Cells were seeded onto 48-well plates at a confluency
of ~60 % (unless stated otherwise) and treated with differ-
ent doses of 3-BrPA, in the presence or absence of the indi-
cated inhibitors (or activators), for 24 h (except describeddifferently). Then, cells were incubated with MTT solution,
for 4 h, and the formazan crystals produced were dissolved
in pure isopropanol. Spectrophotometric absorbance was
measured in a Dynatech MR5000 ELISA microtiter plate
reader (Dynatech Laboratories, Virginia, USA) at 550 nm,
using 630 nm as wavelength of reference. Each assay was
repeated three times, using three wells per experimental
condition. Regarding Figs. 2 and 5, MTT viability rates
obtained from each cocktail of 3-BrPA plus inhibitor/
activator were compared to the respective ones of 3-BrPA
alone and sequentially normalized according to values
derived from inhibitor/activator only, versus its cog-
nate solvent: data were presented in fold (x) of inhibitor/
activator-induced cell survival increase.
Flow cytometry
Control and 3-BrPA-treated cells were initially stained
with 20 μl of AnnexinV-FITC solution, for 20 min at 4 °C
in the dark, and subsequently incubated with 10 μl of
7AAD solution, for 15 min at 4 °C in the dark. All cell
preparations were analyzed within 30 min by flow cytome-
try, using a Beckman Coulter-Cytomics FC500 cell sorter
(Beckman Coulter Inc., California, USA).
T24-specific bladder cancer xenografts in SCID mice: the
new T24-X cell line
NOD.CB17-Prkdcscid/J (SCID) immunodeficient mice
(The Jackson Laboratory, Maine, USA) were used for
bladder cancer xenografts establishment. Mice were
subcutaneously inoculated with ~106 T24 cells per animal
and closely followed till the development of tumors. Each
tumor was carefully excised for cell subculture and serial
passage to another SCID mouse. The whole procedure
was repeated four successive times. Finally, cells extracted
from a tumor of the fourth xenograft passage established
a new line named T24-X (X: xenograft) (Additional file 1:
Figure S1). Animals were treated according to Greek laws
(2015/92), guidelines of European Union and European
Council (86/609 and ETS123, respectively), and in compli-
ance with standards for human care and use of laboratory
animals (NIH, USA, assurance no. A5736-01).
Western blotting
Approximately 40 μg of whole-cell protein extracts were
separated by SDS-PAGE in 10-15 % gels and subsequently
transferred onto nitrocellulose membranes (Whatman-
Schleicher & Schuell GmbH, Dassel, Germany). Blocking
process was carried out through treatment of membranes
with TBS-T containing 5 % NFM (or 5 % BSA), for 2 h at
room temperature. Each primary antibody was added at a
concentration of 1:1000, for 2 h at room temperature and
16 h at 4 °C, while the appropriate IgG-HRP secondary
antibody (anti-rabbit or anti-mouse) was used at a dilution
of 1:2000, for 2 h at room temperature. Immunoreactive
Konstantakou et al. Molecular Cancer  (2015) 14:135 Page 22 of 26bands were visualized by ECL reactions, following man-
ufacturer’s instructions. Actin was used as protein of
reference.
Energy and metabolite assays
Cellular ADP and ATP contents of control and 3-BrPA-
treated cells were determined by a bioluminescence-based
assay, using the ApoSENSOR™ ADP/ATP Ratio Assay Kit
(BioVision Inc., California, USA), according to manufac-
turer’s advice. Processed samples were read in a Tecan
Infinite® M200 microplate reader (Tecan Austria GmbH,
Grödig, Austria) and obtained luminescence signals were
normalized to the number of cells. For lactate detection,
whole-cell lysates of control and 3-BrPA-treated cells were
processed through the Lactate Assay Colorimetric Kit
(BioVision Inc., California, USA), following provider’s in-
structions, and the optical densities of analyzed samples
were measured at 570 nm. Lactate production values were
normalized to the number of cells.
DNA sequencing of PCR products
Genomic DNA from bladder cancer cells was isolated
and subsequently amplified by PCR using B-Raf and K-Ras
gene-specific primers flanking the V600 and G12/G13 cog-
nate codons, respectively (Additional file 9: Table S1).
Cycle sequencing of purified (with Sephadex® G50) PCR
products was carried out using the BigDye® Termin-
ator Sequencing Kit (Thermo Fisher Scientific Inc.-Life
Technologies™-Applied Biosystems®, Massachusetts, USA)
and the processed samples were analyzed on an ABI
Prism® 310 Genetic Analyzer (Thermo Fisher Scientific
Inc.-Life Technologies™-Applied Biosystems®, Massachusetts,
USA). Also, total RNA from 3-BrPA-treated (T24) cells was
reverse transcribed and two GLUT4-specific PCR products,
of 411 bp (Ex7-Ex8) and 336 bp (Ex9-Ex10), were purified
and sequenced as described above (Fig. 7e, Additional
file 5: Figure S5 and Additional file 9: Table S1). All the ob-
tained sequences were compared to available genome as-
semblies created by the Genome Reference Consortium
(http://www.ensembl.org/index.html).
Transient transfection
T24 cells were grown on 6-well plates, in the absence of
antibiotics, to a final confluency of ~90 %. Cells were,
then, incubated for 6 h with 500 μl of Opti-MEM® I Re-
duced Serum Medium (Thermo Fisher Scientific Inc.-Life
Technologies™-Gibco®, Massachusetts, USA), containing
4 μg of purified plasmid DNA [CMV control (empty) vec-
tor or CMV-p53 (over-expressing the wild-type human
p53 protein) vector; kindly provided by Professor Jean-
Christophe Marine (Leuven, Belgium)] and 10 μl of Li-
pofectamine® 2000 (Thermo Fisher Scientific Inc.-Life
Technologies™-Invitrogen™, Massachusetts, USA). Trans-
fection medium was replaced by complete DMEM,supplemented with 10 % FBS, and p53 gene expression
was tested after 48 h of cell growth, at 37 °C and 5 %
CO2, in the presence or absence of 3-BrPA (or
Doxorubicin).
RT-sqPCR
Total RNA from control and 3-BrPA-treated cells was ex-
tracted following a Trizol-based protocol (Thermo Fisher
Scientific Inc.-Life Technologies™-Ambion®, Massachusetts,
USA). RNA (1 μg) was reverse transcribed using an oligo
(dT)12–18 primer and the M-MLV enzyme (Thermo Fisher
Scientific Inc.-Life Technologies™-Invitrogen™, Massachusetts,
USA). cDNA was amplified by sqPCR, with a Biometra
T3000 Thermocycler (Biometra GmbH, Goettingen,
Germany), using gene-specific oligonucleotide primers
(Additional file 9: Table S1). PCR fragments were re-
solved in 2-3 % agarose gels, according to standard pro-
cedures. GAPDH served as gene of reference.
Immunofluorescence
Cells were seeded on poly-L-lysine coated slides (Thermo
Fisher Scientific Inc., Massachusetts, USA) and treated
with 3-BrPA, for 4 h at 37 °C and 5 % CO2 (Fig. 8). Then,
they (together with control slides) were fixed with 4 %
paraformaldehyde, for 20 min at 37 °C and 5 % CO2, and
permeabilized with 0.3 % Triton X-100, for 20 min at
37 °C and 5 % CO2. Slides were blocked with 1 % BSA,
for 90 min at 37 °C and 5 % CO2, and subsequently in-
cubated with a rabbit polyclonal antibody against MCT1
(1:200), for 60 min at room temperature and 16 h at 4 °C.
The anti-rabbit IgG-DyLight® 488 secondary antibody was
used at a dilution of 1:250, for 2 h at room temperature.
Cells were observed under a Nikon Digital Eclipse C1
confocal laser scanning microscope (Nikon Corporation,
Tokyo, Japan).
Statistical analysis
Statistical significance of differences observed in drug-
treated versus control cell values (in the absence or presence
of an inhibitor/agonist) was determined using unpaired,
two-sided Student’s t-test. Data were reported as mean ±
standard deviation of the mean. P < 0.001 was considered
statistically significant.
Additional files
Additional file 1: Figure S1. (related to Fig. 1), Strategy of the
new T24-X cell line establishment, after sequential generation of four
T24-derived tumor xenografts (small arrows) in SCID mice. As shown
by light microscopy -representative- imaging, apart from the (frequent)
presence of few cytoplasmic vacuoles exclusively observed in T24-X, the T24
and T24-X cells presented with almost identical morphological features.
Scale bars: 7 μm.
Additional file 2: Figure S2. (related to Fig. 2), (A) Doxorubicin serves
as drug of reference for autophagy induction in RT4, but not T24, cells.
Konstantakou et al. Molecular Cancer  (2015) 14:135 Page 23 of 26Representative (one out of three experiments) Western blotting profiles
of the indicated autophagic proteins in control (−) and Doxorubicin-treated,
for 24 h, RT4 and T24 cells (~60 % confluency). (B) Quick and massive
depletion of ATP stores in 3-BrPA-treated T24 cells (also, see Fig. 1c).
Quantitative assessment of ADP/ATP ratio (x) after exposure of T24 cells
(~60 % confluency) to 3-BrPA (50–150 μM) for 30 min. (B) Data are denoted
as mean ± standard deviation of triplicates of three independent experiments.
*P < 0.001.
Additional file 3: Figure S3. (related to Fig. 3), (A) 3-BrPA cannot induce
phosphorylation of p53 protein on its critical serine residues 9, 20, 37 and 46,
in T24 cells. (B) Doxorubicin serves as drug of reference for phosphorylation
of p53 protein on its critical serine residues 9, 20, 37 and 46, in RT4 cells. (A-B)
Representative (one out of three experiments) Western blotting profiles of
the indicated p53 phosphorylated protein forms in T24 (A) and RT4 (B) cells
(~60 % confluency), after their exposure to 3-BrPA (A) and Doxorubicin
(B), respectively, for 24 h.
Additional file 4: Figure S4. (related to Fig. 6), RT112 and TCCSUP
cells carry wild-type B-RafV600 and K-RasG12/G13 alleles. DNA sequencing
chromatograms (three independent experiments) of B-Raf (left panel)
and K-Ras (right panel) genomic PCR products amplified from RT112
and TCCSUP cells, using gene-specific oligonucleotide primers flanking
the V600 and G12/G13 cognate codons, respectively (also, see Additional file 9:
Table S1 and Additional file 10: Table S2).
Additional file 5: Figure S5. (related to Fig. 7), (A) Gene expression of
Rab family members undergoes severe perturbation in 3-BrPA-treated
bladder cancer cells. Representative (one out of three experiments)
RT-sqPCR profiles of Rab2A, Rab8A and Rab14 genes in RT4, T24 and
T24-X cells (~60 % confluency), after their treatment with 3-BrPA for
24 h. (B) Structural organization (schematic presentation) of the unprocessed
GLUT4 RNA -two- major splicing variants Sv001 and Sv004, with arrows
denoting the position and orientation of each primer’s annealing activity
(http://www.ensembl.org/Homo_sapiens). E: exon. I: intron. White rectangle
(s): untranslated region(s). (C) 3-BrPA compels the GLUT4-specific introns’
retention in T24 cells. DNA sequencing chromatograms (three independent
experiments) of Exon 7 - Intron 7/8 - Exon 8 (upper panel) and Exon 9 - Intron
9/10 - Exon 10 (lower panel) RT-sqPCR (unspliced) products of 411 and
336 bp, respectively, derived from T24 cells (~60 % confluency) after their
exposure to 75 μM of 3-BrPA for 24 h (also, see Fig. 7e and Additional file 9:
Table S1). F/R: forward/reverse oligonucleotide primer (position and orientation).
Gray triangle(s): exon-intron junction(s).
Additional file 6: Figure S6. (related to Fig. 7), 3-BrPA affects transcriptional
activity in gene-specific and necrotic dose-dependent manner in T24
cells. Representative (three independent experiments) RT-sqPCR profiles
of the indicated genes in T24 cells (~60 % confluency) treated with 75–150 μM
of 3-BrPA for 24 h. The genes examined have previously proved to: (a) critically
modulate apoptosis (e.g. APAF1, BOK, BIM, BAX, BIK, PUMA, NOXA, BCL-2, XIAP,
cIAP-1, MCL-1, BCL-XL, SURVIVIN, DR4 and DR5), (b) represent p53 bona fide
targets (e.g. BAX, PUMA, NOXA, TIGAR and SESTRIN-1), (c) code for signaling
transmembrane receptors -controlling apoptosis and cellular metabolism- (e.g.
DR4, DR5, IGF-1R and CD44), (d) produce transcription factors -orchestrating
tumor establishment- (e.g. HIF-1α and c-MYC), (e) regulate cellular metabolism/
glycolysis (e.g. IGF-1R, CD44, PGM1, PFKM, TIGAR, LDH-A, HIF-1α and c-MYC), (f)
control cancer development (e.g. BAX, BCL-2, HIF-1α and c-MYC), (g) synthesize
proteins implicated in hypoxia (e.g. HIF-1α), (h) direct mitochondrial functions
(e.g. c-MYC, LONP1, SCO2 and COX4i1) and (i) advance cell cycle (e.g. CYCLIN-D1).
Note the strong downregulation of transcriptional activity in the majority of
genes examined, particularly at the highly necrotic doses of 3-BrPA.
Nevertheless, PUMA, NOXA, LDH-A, HIF-1α and CYCLIN-D1 (and GAPDH;
Fig. 7) genes appeared comparably unaffected, thus indicating the
gene-specific cytotoxic character of 3-BrPA in T24 cells. Interestingly,
the p53-target genes PUMA and NOXA remained rather unharmed, while
BAX, TIGAR and SESTRIN-1 ones followed (necrotic) dose-driven reduction of
their expression levels, in response to the drug, further corroborating the
engagement of p53-independent cyto/genotoxic routes in 3-BrPA-treated
bladder cancer cells (Fig. 3).
Additional file 7: Figure S7. (related to Fig. 7), (A-C) T24 and T24-X, but
not RT4, cells suffer from weakly irregular splicing of G6PD and
MCT1 unprocessed RNA transcripts in response to 3-BrPA: a drug-
specific dysfunction. Representative (three independent experiments) RT-sqPCR profiles of G6PD (A and C) and MCT1 (B) genes in bladder cancer
cells (~60 % confluency), after their exposure to 3-BrPA (A-B), Taxol and
Doxorubicin (C) for 24 h. Note the absence of G6PD and MCT1 aberrant
splicing forms in 3-BrPA-treated RT4 cells (A-B), and the generation of
G6PD atypical splicing variants in T24 (and T24-X) cells, after their treatment
with 3-BrPA (A) or Taxol (C; left panel), but not Doxorubicin (C; right panel).
Additional file 8: Figure S8. (related to Fig. 2), (A-C) Dispensable role
of AIF in 3-BrPA-driven regulated death of T24 cells. (A-B) Representative
(three independent experiments) immunofluorescence images of AIF
expression and cellular localization in T24 cells (~60 % confluency), grown in
the absence (−) or presence of 3-BrPA for 30 min, 2 h (A) and 4 h (B). Note
the cytoplasmic retention and non-nuclear compartmentalization of AIF
protein (employment of a rabbit polyclonal antibody used at a dilution of
1:200), not only in control (−) cells but also in ones exposed to 3-BrPA
(related to Fig. 2a-b). Cells were observed under a Nikon Digital Eclipse
C1 confocal laser scanning microscope. Green (anti-rabbit IgG-DyLight®
488) and red (anti-rabbit IgG-DyLight® 650) colors: AIF -cytoplasmic-
topology. Blue color: nuclear DNA counterstaining (DAPI). Scale bars:
2 μm. (C) Representative (three independent experiments) Western
blotting profiles of AIF protein (whole-cell protein extracts) in T24 cells
(~60 % confluency), treated with 3-BrPA for 24 h. Note the dose-dependent
reduction of AIF cellular content.
Additional file 9: Table S1. (related to Figs. 6–7, Additional file 4:
Figure S4 and Additional file 5: Figure S5), Gene names, oligonucleotide
primer sequences (F: forward; R: reverse), molecular sizes (bp) of the
amplified PCR products and PCR protocol details (annealing temperature
and number of cycles) for the herein examined genes (Figs. 6–7).
Ta: annealing temperature. Ex: exon. In: intron. Sv: splicing variant.
Additional file 10: Table S2. (related to Figs. 1, 5 and 6, and Additional
file 4: Figure S4), Sensitivity of bladder cancer cells to 3-BrPA seems to tie
in with malignancy grade, but not mutant B-RafV600 or K-RasG12/G13 oncogenic
profile - an inverse relation between resistance to 3-BrPA (e.g. RT4 and RT112
cells; low grade) and tolerance to glucose deprivation (e.g. T24, T24-X and
TCCSUP cells; high grade).
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